We rank #3 in the anti-diabetic market in India with significant market share.
We have established a strong presence in our anti-diabetes segment through comprehensive portfolio therapies and patient-centric initiatives that support long-term disease management.
We rank #3 in the anti-diabetic market in India with significant market share.
We hold a strong presence across oral anti-diabetic therapies, insulin products, and combination treatments.
Two of our diabetes medicines (Gluconorm-G and Huminsulin) rank among the top 300 brands in the IPM (Indian Pharma Market).
We continue expanding our diabetes portfolio through strategic acquisitions and collaborations.
Our approach to diabetes care extends beyond medicines to include patient education, digital tools, and professional healthcare engagement to improve long-term outcomes.
HuMrahi is our patient support program for diabetes and cardiac care, supporting thousands of patients, by offering personalized counseling, monitoring tools, free medication and tests, across India.
Our anti-diabetes portfolio addresses multiple stages of disease progression and patient needs across various care settings.
Chronic metabolic disorder where the body becomes resistant to insulin and where support requires control through oral anti-diabetic medicines and combination therapies.
A chronic autoimmune condition where pancreas produce little or no insulin. Supported through insulin therapies and education initiatives.
Diabetes significantly increases the risk of cardiovascular conditions such as heart disease and stroke. Care initiatives help manage blood glucose and associated cardiac risks.
Obesity is a chronic, long term disease caused by excess fat accumulation that often requires ongoing medical management and can interfere with everyday life. It is a serious condition, with distinct causes, symptoms, and complications. Obesity is also strongly linked to 200+ comorbidities, including heart diseases, diabetes, stroke, and cancer.
Uncontrolled diabetes can lead to complications affecting the kidneys, nerves, eyes, and heart. Long-term management is imperative in this case for improved lifestyle and health outcomes.
Disclaimer: The content on this website/webpage relates to a specific therapy/therapeutic area and is intended solely for informational and educational purposes for healthcare professionals and patients across India and other global locations, is not intended to substitute professional medical advice, diagnosis, or treatment. Advice from a physician or other qualified healthcare professional must be sought for any queries regarding a medical condition or treatment. Information on this website/webpage should not be solely used or relied upon in the absence of or delay in receiving professional medical advice. While Lupin makes reasonable efforts to ensure that the information is accurate and up to date, it makes no representations or warranties regarding its completeness or accuracy and accepts no liability for reliance on such information. The information on this website/webpage is not a substitute for prescribing information or patient information leaflets accompanying any medicinal product. The information on this website/webpage is subject to change without notice and may not reflect the most current medical, scientific, or regulatory developments. All content on this website/webpage is the intellectual property of Lupin and shall not be reproduced, modified, distributed, or used for any commercial purpose without the prior written consent of Lupin.
We at Lupin have built a robust anti-diabetes portfolio which supports comprehensive care through oral therapies, insulin products, advanced devices, and combination treatments.
Our leading brand used in the management of T2DM, combines glimepiride and metformin. It is designed to help the body use insulin better and supports steady sugar control.
Our insulin therapy, which is available across India, is used to manage diabetes mellitus and helps improve glycemic levels. Huminsulin offers a range of insulin options to support consistent blood glucose management.
GIBTULIO® is used in the treatment of type 2 diabetes. It contains empagliflozin, which supports blood sugar control along with cardiovascular health across a broad range of patients.
Linagliptin is used in the management of type 2 diabetes and supports glycemic control across a broad range of patient needs.
Our next-generation therapy for type 2 diabetes and obesity management supports weight reduction while offering comprehensive benefits and addressing multiple metabolic risks together.
Ajaduo® combines empagliflozin and linagliptin and is used for the management of type 2 diabetes. It supports glycemic control and may support cardiovascular and renal outcomes.
Through these products and ongoing portfolio expansions, we continue to strengthen our position as a trusted provider of diabetes management therapies across global markets.
We continue to expand our diabetes care initiatives through patient programs, healthcare education, and digital engagement platforms.
Diabetes continues to pose as one of the most significant global health challenges, requiring sustained innovation, accessible therapies, and stronger patient engagement.
At Lupin, our commitment to diabetes management is to ensure high-quality, accessible medication and care that goes beyond the pills.
Through scientific rigor, ongoing strategic partnerships, and patient support programs, we strive to take one step each day towards our goal, which is to enable better outcomes for millions of people living with diabetes worldwide.
